Fresenius Kabi SwissBioSim GmbH clinical trials
Acquired by Fresenius Kabi, 2017 · source ↗
The registry lists 10 studies whose lead sponsor is Fresenius Kabi SwissBioSim GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 11, 2025.
Before and after it joined Fresenius Kabi
- First submitted before Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- 1
- First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- 4
- Unclear, or no submission date
- 5
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Fresenius Kabi SwissBioSim GmbH10 studies
Something wrong with this grouping? Tell us on the Fresenius Kabi page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Fresenius Kabi studies →
- Real World Use of Tocilizumab Biosimilar studYActive, not recruitingNCT06247722
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With OsteoporosisCompletedNCT04934072Phase 3
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- MSB11022 in Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02660580Phase 3
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted before Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- MSB11456 in Participants With Moderately to Severely Active Rheumatoid ArthritisCompletedNCT04512001Phase 3
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- Comparison of PK and Tolerability of MSB11022 Administered by AI or PFSCompletedNCT04018599Phase 1
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · First submitted after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456CompletedNCT03282851Phase 1
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- MSB11022 in Moderate to Severe Rheumatoid ArthritisCompletedNCT03052322Phase 3
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy SubjectsCompletedNCT03251248Phase 1
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- Safety and Immunogenicity of MSB11455 in Healthy ParticipantsCompletedNCT03251339Phase 1
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi
- MSB11022 in Healthy SubjectsCompletedNCT03014947Phase 1
Sponsor listed in the registry: Fresenius Kabi SwissBioSim GmbH · Unclear whether first submitted before or after Fresenius Kabi SwissBioSim GmbH became part of Fresenius Kabi